Monday , January 17 2022

Improving dementia – vaccination with a new vaccine could prevent the symptoms of Alzheimer's disease



[ad_1]

A new study shows that a vaccine presented to the skin encourages an immune response that reduces the harmful and beta-amyloid fire – without stimulating severe inflammation to the brain that produced antibody treatments earlier in some patients.

Professor Roger Rosenberg, organizational director of Alzheimer's Disease Center at the University of Southwest Texas in the United States, said: "This study is the culmination of a decade of research that has repeatedly shown that this vaccine can target & # 39; n Effective and safe in animal models what we can think of Alzheimer's disease.

"I think we're about to experience this therapy among people."

The findings, published in the Alzheimer's Research and Therapy magazine, show how a DNA that supersedes a beta-amyloid segment also reduces tau in mice who have been modeling for Alzheimer's disease.

The vaccine also draws attention to different immunity that can be safe for people.

Two previous studies of the Prof. Rosenberg laboratory showed similar immune responses in rabbits and monkeys.

The vaccine is a shortlist of promising antibody treatments that have aimed at protecting against both types of protein that kill the cells of the brain as they spread in dead plaques and strains on the patients' brain disease Alzheimer's.

Although earlier research establishes the fact that antibodies are significantly reducing amyloid in the brain, Professor Rosenberg's team needed to find a safe way to present to the body.

A vaccine that was developed elsewhere prompted pledge in the early 2000s, but when it was tested in humans, it caused swelling of the brain in some patients.

Professor Rosenberg's idea was to start coding DNA for amyloid and to spray the skin instead of muscle to produce a different type of immune response.

Injected skin cells make a three-molecule chain of beta-amyloid, and the body responds by producing antibodies that also prevent an amyloid and indirect assault of two.

The latest study – which includes four groups between 15 and 24 mouse each – shows that the vaccine stimulates a 40 per cent reduction in beta-amyloid and up to 50 per cent reduction in tau , without any adverse immune response.

Professor Rosenberg's team predicts that if Amyloid and Tau are true of Alzheimer's disease, since achieving such human reductions could have a large therapeutic value.

Senior writer Dr Doris Lambracht-Washington said: "If the disease started could be delayed by even five years, that would be huge for patients and families.

"The incidence of dementia can drop half."

Alzheimer's disease is characterized by the increasing decline of the brain as the neurons are destroyed.

There is no effective treatment, although many antibodies and other therapies are investigated and tested in clinical trials to target amyloid plaques and tube tubes – the two characteristics of the disease.

One strategy, which is still proven for clinical benefits, means the production of antibodies in the laboratory and spraying into the body – a technique referred to as passive immunization.

Professor Rosenberg said, allowing the body to produce its own antibodies through active immunization that would be the better strategy, if it can be done safely.

Among the benefits, he said the vaccine would be more accessible and less expensive. It also produces a wider variety of pre-formed antibodies or antibodies that contain only one specific antibody.

Scientists have also been trying to develop an Alzheimer's diagnostic approach at the earliest stage so that developing therapy could be given in the future before the brain declined.

Professor Rosenberg added: "The longer you wait, the less likely to be the same.

"Once the plaques and angles have formed, it can be too late."

[ad_2]
Source link